Patients carrying a C9orf72 repeat expansion leading to frontotemporal dementia and/or amyotrophic lateral sclerosis have highly variable ages at onset of disease, suggesting the presence of modifying factors.
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C9orf72 (OMIM 614260) repeat expansions are the most common genetic cause of familial FTD (25% of cases) and familial ALS (37% of cases). 2 Up to 88% of patients with familial FTD or ALS with both clinical phenotypes have the C9orf72 repeat expansion. 3, 4 Highly variable ages at onset have been reported in individuals who carry the C9orf72 repeat expansion, which is suggestive of the influence of modifying factors. [5] [6] [7] In a Belgian cohort, evidence was provided for the existence of repeat expansions as short as 45 repeat units that are pathologic. 5 The study also showed that short repeat expansions of less than 80 repeat units are inversely correlated with later ages at onset. Repeat expansions of more than 80 repeat units are difficult to size accurately because of their large size-up to 4400 repeats corresponding to near 27 Kb 8 -and the enormous variability in repeat sizes produced by somatic mosaicism masking the true length of the C9orf72 repeat expansion. However, an association was observed between the methylation state and the expansion size in blood and the brain. Consequently, the degree of methylation, which is measurable, is a reflection of the repeat expansion size. In informative C9orf72 parent-child transmissions, earlier ages at onset, increasing expansion sizes, and/or increasing methylation states were identified in accordance with disease anticipation. 5 Disease anticipation is a well-known phenomenon occurring in repeat expansion disorders that affects expression of the disease. Repeat expansions are dynamic mutations in which the copy number of simple DNA repeats is unstable. Consequently, these repeats are at risk of changes in repeat size when they are transmitted to the next generation. Clinically, in several repeat expansion disorders, a decrease in age at onset of the disorder is observed in successive generations. [9] [10] [11] In addition, in later-born generations the clinical phenotype becomes more severe in association with increasing repeat expansion sizes.
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The risk of increased repeat expansion in successive generations can be influenced by several factors. In Huntington disease, larger expansions are less stable than shorter ones and disease anticipation is more common in paternal transmissions, 13 while in other repeat expansion diseases anticipation can be predominant in maternal inheritance. 11 A decrease in repeat size can also occur, which might be influenced by the sex of the parent who transmits the repeat.
Because of the enormous size of the C9orf72 expansions in most carriers, it remains difficult to gather enough experimental proof for a role of genetic anticipation in most transmissions. Therefore, we aimed to provide additional clinicalbased evidence for the occurrence of disease anticipation in families carrying a C9orf72 repeat expansion by analyzing age at onset, disease duration, and age at death in successive generations.
Methods

Study Population
We investigated families with a C9orf72 repeat expansion ascertained in Belgium. The index patients of these families belong to large cohorts of patients with a clinical diagnosis of FTD (n = 462), ALS (n = 215), both clinical phenotypes (n = 46), or Alzheimer disease dementia (n = 1221). Recruitment of patients took place from June 16, 2000, to June 1, 2016, by neurologists of different university and general hospitals, collaborating in the framework of the Belgian Neurology Consortium. Index patients were evaluated using a protocol that included a detailed personal and familial medical history, clinical neurologic examination, neuropsychological testing, biochemical analyses, and neuroimaging. The diagnosis of FTD was made according to the international consensus criteria. 14 19 All available medical records were reviewed by a physician on the research team (S.V.M.). Index patients and their relatives were contacted by trained research nurses (K.P. and M.M.). Detailed information on family history of dementia and/or ALS was gathered, and family members were asked to participate in genetic studies. Written informed consent for participation in the genetic studies was obtained from participants or their legal guardians. The informed consent forms for patient ascertainment were approved by the local ethics committees of each of the collaborating neurological centers (Antwerp University Hospital, University Hospitals Leuven, University Hospital Ghent, University Hospital Brussels, Saint-Luc University Hospital Liège, Hospital Network Antwerp, General Hospital Sint-Jan BruggeOostende, General Hospital Sint-Maria Halle, and Jessa Hospital Hasselt). The genetic study protocols and informedFamilies of index patients carrying a C9orf72 repeat expansion were included in the current study if information was available about the ages at onset and/or ages at death of clinically affected individuals or unaffected family members carrying a C9orf72 repeat expansion in at least two generations, after exclusion of the youngest generation with no affected family members carrying a C9orf72 repeat expansion yet. A total of 36 families were included in the study. The ages of individuals who died at a young age (<25 years) without development of the disease were excluded. To reduce bias to cohort effects, we numbered the earliest-born generation in each pedigree as generation 4 irrespective of the amount of generations with available age data, creating a mixture of birth cohorts across generations (eTable 1 in the Supplement). Information on which family members were clinically affected, regardless of whether blood samples were available, was gathered by a physician (S.V.M.) and trained research nurses (K.P. and M.M.). Clinical files of affected family members were collected and reviewed. The ages at onset of affected family members were determined as the age at which the first symptoms occurred, based on information in the clinical files or information received from living relatives if no clinical files were available (eTable 1 in the Supplement).
Statistical Analysis
We used mixed effects Cox proportional hazard regression models (Coxme package in R [The R Foundation for Statistical Computing]) to study the generational effect on age at onset, age at death, or disease duration. This family-based analysis gives information on more than 1 consecutive generation and enabled us to account for the degree of kinship (determined using kinship2 in R) in the model, and allowed us to include both affected and unaffected individuals. In the initial mixed effects Cox proportional hazard regression models, kinship, family, sex, phenotype, source of information about age at onset (personal clinical file, clinical file of relative, or hearsay from living relative) (in models for age at onset and disease duration), mean life expectancy per birth cohort of 25 years (based on data from the Federal Public Service Statistics Belgium) (in models for disease duration and age at death), age at onset (in model for disease duration), and disease duration (in model for age at death) were included as covariates. In the final mixed effects Cox proportional hazard regression models, the covariates only included those with a significant effect (P ≤ .05) in the initial model.
Unaffected individuals were included in the model for age at onset and censored at the age of last evaluation. Affected individuals still alive were included in the model for disease duration and censored at the age of last evaluation. In the model for age at death only affected individuals were included.
For the comparative analysis of the difference in age at onset between a mother and her offspring and a father and his offspring, an independent t test was used (normal distribution of difference in age at onset). When ages at onset were available for several affected children of 1 parent, the median age at onset of the children was used. All statistical testing was 2-tailed and the level of significance was set at P < .05. Table 1) . For this study, the diagnoses were grouped into 3 phenotypes: pure dementia, ALS, and combined FTD-ALS. The first group included patients with an FTD diagnosis as well as those with a diagnosis of unspecified dementia, Alzheimer disease dementia, and PD with dementia. Of the 36 families, 21 had available age data in 2 generations, 13 in 3 generations and 2 in 4 generations (eTable 1 in the Supplement).
Results
Descriptive
Age at Onset
Individuals in later-born generations were more likely to develop disease at an earlier age, with a risk estimate (SE) of 1.98 (0.20) (P < .001 for trend) ( Figure) . When the analysis was restricted only to individuals identified as carrying the expansion, age at onset still decreased significantly across successive generations, with a risk estimate (SE) of 1.66 (0.21) (P = .01) (eTable 2 in the Supplement). In the analysis restricted only to individuals identified as carrying the expansion, sex was significantly associated with age at onset, with a risk estimate (SE) of 0.44 (0.28) (P = .003), with an earlier age at onset in males.
To investigate the influence of the sex of the transmitting parent on the occurrence of disease anticipation, we compared the mean (SD) difference in age at onset between an affected mother and her affected offspring (n = 14; 4.8 [9.4] years) with the mean (SD) difference in age at onset between an affected father and his affected offspring (n = 17; 9.9 [7.5] years); no significant difference was found (P = .11). When only transmissions were taken into account with an identified C9orf72 expansion in both the parent and the child, there was also no significant difference between the mean (SD) difference in age at onset between an affected mother and her affected offspring (n = 6; 5.4 [10.2] years) and the mean (SD) difference in age at onset between an affected father and his affected offspring (n = 11; 10.0 [7.7] years) (P = .32). 
Disease Duration
Discussion
In accordance with other diseases associated with repeat expansions, one might expect that the onset of C9orf72-associated disease is linked with repeat length and that genetic anticipation occurs when the repeat expansion is transmitted to the next generation. Although other reports could not reveal an association between repeat length and age at onset, 8,20-28 a recent study has demonstrated an inverse correlation between short repeat expansions and later ages at onset, owing to an assay that allowed the precise measurement of repeat sizes shorter than 80 repeat units (ie, short expansions). 5 However, few individuals who carried short expansions were identified in our cohort; therefore, a thorough study of disease anticipation in parent-offspring pairs in which the parent carried a short expansion and the offspring carried a long expansion (>80 units) was not possible and did not allow firm conclusions to be drawn regarding the occurrence of genetic anticipation in families carrying the C9orf72 repeat expansion (eTable 3 in the Supplement). Therefore, we aimed to provide clinical evidence to support the hypothesis of disease anticipation. In accordance with other diseases associated with repeat expansions, we clinically expect ages at onset to become earlier and disease to become more severe in successive generations as a result of genetic anticipation (ie, repeat amplification). We estimated the generational effect on age at onset, disease duration, and age at death in 36 extended pedigrees using a mixed effects Cox proportional hazards regression model. This is a more powerful approach compared with affected parent-child pairs since unaffected individuals are also included in this analysis, which avoids right-truncation bias 29,30 resulting from excluding individuals who might develop disease after the study is concluded. In accordance with the expectations of genetic anticipation, we observed a significant decrease in age at onset over successive generations. Similar to results of a published study, 31 we could not determine a significant effect of parental sex since the difference in age at onset between father and offspring and between mother and offspring was not significantly different. However, the number of affected parent-offspring pairs with available ages at onset was too small to draw any firm conclusions.
To study the hypothesis of more severe disease in successive generations, we analyzed the generational effect on disease duration. A correlation between disease duration and repeat length was reported in the cerebellum but not in the frontal lobes. 23 Our results of a lack of association between disease duration and generation could imply that cerebellar repeat length does not increase in successive generations, while frontal repeat length might or might not repeat. Another marker of disease severity can be the incidence of ALS, which might be considered a more severe phenotype than FTD. Some : apart from diagnoses of FTD and/or ALS, patients in our cohort received diagnoses of Alzheimer disease dementia, PD, PD plus dementia, and unspecified dementia. For our analyses, we categorized all patients with a dementia diagnosis without ALS together in 1 group. The motivation to do so was not only statistical power, but also because many of these patients might actually have FTD. Fifty-one affected individuals had a diagnosis of Alzheimer disease dementia, PD plus dementia, or unspecified dementia; however, the diagnosis was based on the clinical record in only 13 patients. Consequently, many patients lacked diagnostic workup by a neurologist, which is particularly relevant since previous reports have shown that Alzheimer disease dementia or PD are likely clinical misdiagnoses since C9orf72 repeat expansions are very rarely found in pathologically confirmed Alzheimer disease or PD.
39,41
Whether an individual carrying the C9orf72 repeat expansion develops FTD, ALS, or both might be influenced by several factors other than repeat length. Chiò et al 31 argued for an association between the phenotype of the parent and the phenotype of the child. We confirmed this finding in our data (eTable 4 in the Supplement): a parent with cognitive decline is more likely to have an affected child who manifests symptoms of cognitive decline and, similarly, an affected child is more likely to develop ALS if the parent has ALS. As for disease duration, we could not detect a significant difference of age at death between generations. The rationale to study age at death was that age at death could be a more objective marker than age at onset, since it cannot be influenced by recall bias. However, age at onset is directly determined by C9orf72-associated disease, while age at death, especially in patients with dementia, is generally instigated by other comorbidities. We included life expectancy as a covariate in the analysis of age at death to correct for surveillance that better treatment of comorbidities results in later age at death in successive generations. If genetic anticipation does occur in C9orf72-associated disease, our results indicate that the C9orf72 repeat expansion length would not determine age at death, as previously reported.
33 This is in contrast to Huntington disease, in which a significant association of the HTT (OMIM 613004) CAG expansion with age at death was recently found.
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A complication in the study of the clinical consequences of disease anticipation is that not only repeat expansion size but also several other factors might be influencing clinical characteristics of C9orf72-associated disease. Chiò et al 31 suggested that the clinical phenotype influences age at onset since they observed that the co-occurrence of FTD increases age at onset in patients with ALS. In our study, we could not demonstrate a significant association between age at onset and clinical phenotype, but age at death was significantly earlier in patients with ALS than in those with pure dementia. Consequently, disease duration was significantly shorter in patients with ALS with or without FTD. Another factor that could act as a modifier is sex. We could not entirely confirm the observation of Williams et al 43 that males were significantly more likely to develop C9orf72-associated ALS at a younger age: we only observed an earlier onset of C9orf72-associated disease in males in the analysis restricted only to individuals identified as carrying the expansion. Additional studies of a potential effect of sex on age at onset are necessary.
Limitations
Our study has some limitations. First, we had to rely on information about age at onset obtained from relatives in 49 of 111 patients (44.1%), mostly from older generations, increasing the risk for recall bias. However, source of information about age at onset was not significantly associated with age at onset. Moreover, Minikel et al 44 stated that the inclusion of data on individuals ascertained retrospectively through family history can reduce or even eliminate a false signal of disease anticipation. A second limitation is that we were unable to prove experimentally the carrier status in 31 of 111 patients (27.9%) with age at onset data, and thus we could not exclude the potential inclusion of phenocopies in the families or sporadic patients with late-onset Alzheimer disease dementia. A third factor that could distort our findings is that relatives in the later-born generations might recognize the disease earlier because they are more familiar with the symptoms. Unfortunately, statistical methods to fully resolve this issue are lacking. In an attempt to decrease this factor of bias, we performed an additional analysis including only ages at onset that were determined by a physician, which still resulted in a significant generational effect on age at onset (risk estimate [SE], 3.66 [0.30]; P < .001) (eTable 5 in the Supplement). Finally, recall bias and societal generational aspects can lead to an overestimation of the anticipation in age at onset. However, an effort was made to account for as many as possible (known) factors of bias in this study and we believe we have provided a valuable study adding arguments for the occurrence of disease anticipation in C9orf72-associated disease. Nevertheless, additional clinical and molecular studies are necessary to confirm our findings and provide additional evidence.
Conclusions
We provided clinical data supporting the occurrence of disease anticipation in families carrying the C9orf72 repeat expansion by means of an earlier age at onset in successive generations. Our results suggest that, in contrast with other diseases associated with repeat expansion, disease anticipation results in earlier ages at onset but not in more severe phenotypes. Our finding may help clinicians decide from which age onward it may be relevant to clinically follow up presymptomatic individuals who carry the C9orf72 repeat expansion. Of the patients with onset age data included in the current study, 72.1% were identified as C9orf72 repeat expansion carriers (proved on DNA or obligate carriers). In three affected carriers a short C9orf72 repeat expansion of < 80 units was identified allowing an accurate repeat sizing 1 . Another eight unaffected carriers were identified with a short expansion of < 80 units, resulting in a total of 11 'short' repeat expansion carriers in five of the families included in the analyses. In two other families not included in the clinical analyses (because age information was only available for one generation after exclusion of the youngest unaffected generation), DR439 and DR911, four additional short expansion carriers were found. Solely based on genetic results, we demonstrated genetic anticipation ('short' to 'long' repeat expansion) from parent to child in families DR439, DR819 and DR896, and genetic contraction ('long' to 'short' repeat expansion) from parent to child in families DR1258 and DR912 1 . Only a minority of the 'short' expansion carriers were affected and informative to study clinical consequences of genetic anticipation/contraction. In DR439, In this mixed effects Cox proportional hazard analysis, affected individuals with onset ages derived from a personal clinical file were included (n= 62) as well as unaffected individuals with ages at last evaluation (n= 92). A high significant association was found between generation and onset age (p= 1.3*10 -5 ) with a significant higher likeliness to develop C9orf72 related disease at an earlier age in successive generations. No other covariates (source of information on onset age, sex, phenotype) were significantly associated with onset age.
